Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.41Last Year’s EPS
-0.4Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in revenue growth, both domestically and internationally, and improvements in gross margins and tariff conditions. The company has increased its financial guidance for the year and received a positive update on Medicare reimbursement. However, there are concerns over leadership changes and financial metrics like net loss and adjusted EBITDA, although these are improving. Overall, the positive aspects outweigh the challenges.Company Guidance
Strong Quarterly Revenue Growth
Total revenue for the second quarter of 2025 was $79.2 million, representing growth of 48% compared to the second quarter of 2024. U.S. revenue for the second quarter was $69.6 million, representing growth of 46% compared to the prior year period.
Record International Revenue Performance
International revenue in the second quarter of 2025 was $9.6 million, representing growth of 69% compared to the prior year period, driven primarily by strong sales momentum in the United Kingdom, Japan, and Korea.
Gross Margin Expansion
Gross margin for the second quarter of 2025 was 65.4%, representing an increase of 640 basis points year-over-year.
Positive Outlook on Medicare Reimbursement
CMS announced Aquablation therapy was assigned a Category I code effective January 1, 2026, with a proposed payment higher than TURP, marking a significant milestone for PROCEPT.
Improved Tariff Situation
Chinese tariff rates have declined from 1045% to approximately 55%, reducing the estimated cost of goods sold headwinds in the second half of 2025 from approximately $5 million to $1 million to $2 million.
Increased Financial Guidance
Full year 2025 total revenue is now expected to be approximately $325.5 million, up from previous guidance, representing growth of approximately 45% compared to 2024.
PRCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $45.69 | $39.59 | -13.35% |
Apr 24, 2025 | $55.70 | $52.56 | -5.64% |
Feb 25, 2025 | $62.71 | $68.11 | +8.61% |
Oct 28, 2024 | $68.77 | $91.00 | +32.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PROCEPT BioRobotics (PRCT) report earnings?
PROCEPT BioRobotics (PRCT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is PROCEPT BioRobotics (PRCT) earnings time?
PROCEPT BioRobotics (PRCT) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRCT EPS forecast?
PRCT EPS forecast for the fiscal quarter 2025 (Q3) is -0.41.